Adverse Clinical Effects of Botulinum Toxin Intramuscular Injections for Spasticity

摘要: Objective: The adverse events (AEs) with botulinum toxin type-A (BoNTA), used for indications other than spasticity, are widely reported in the literature. However, site, dose, and frequency of injections different spasticity when compared to treatment conditions hence AEs may be as well. objective this study was summarize Canada systematically review intramuscular treat focal spasticity. Methods : Data were gathered from Health (2009-2013) major electronic databases. Results In a 4 year period, 285 reported. OnabotulinumtoxinA (n=272 events): 68% females, 53% serious, 18% hospitalization, 8% fatalities. type – muscle weakness (19%), oropharyngeal (14%), respiratory eye related (8%), bowel/bladder infection (5%). IncobotulinumtoxinA (n=13): 38% 62% 54% hospitalization. (15%), (38%), (23%), (15%). Commonly literature weakness, pain, oropharyngeal, bowel/bladder, blood circulation, neurological, gait, problems. Conclusion: While BoNTA is useful managing future studies need investigate factors that can minimize AEs. A better understanding underlying mechanisms also improve guidelines administration enhance outcomes.